TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics to Present at Upcoming March Investor Conferences

TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial

TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts